title: [News about targeted therapies in non-small-cell lung cancer in 2015 (except immuno-therapy)].
abstract: Recently, developments of therapies that target abnormally activated signaling pathways are increasing for patients with non-small cell lung cancer. EGFR mutations are found in about 10% of lung cancers, especially in adenocarcinoma, women and non-smokers. Three EGFR inhibitors (erlotinib, gefitinib and afatinib) received a European marketing authorization for up to first line treatment of EGFR mutated NSCLC. Effectiveness of EGFR inhibitors is higher than conventional chemotherapy. Third generation EGFR inhibitors (rociletinib, AZD9291) are effective for patients who develop a resistance mutation such as T790M resistance mutation; they obtained temporary authorization for use in France in 2015. The EML4-ALK translocation is found in about 5% of NSCLC and more particularly in adenocarcinoma of young non-smoking patients. Crizotinib is a new therapeutic standard in ALK translocated NSCLC in second line. Ceritinib is a 2nd generation ALK inhibitor which received a European marketing authorization for up to treatment of ALK translocated NSCLC after progression with crizotinib. INCA supports ACSé program evaluating the efficacy of crizotinib in NSCLC amplified for MET or translocated for ROS1 and ACSé program evaluating the efficacy of vemurafenib in tumors non melanoma mutated V600E BRAF. The role of other biomarkers such as KRAS, BRAF, HER2 and PI3KCA mutations remains to be defined in NSCLC.
authors.affiliation: GRC 04 UPMC, hôpital Tenon, Assistance Publique-hôpitaux de Paris, 4, rue de la Chine, 75970 Paris cedex 20, France.
authors.forename: Cécile
authors.initials: C
authors.lastname: Hamard
authors.affiliation: GRC 04 UPMC, hôpital Tenon, Assistance Publique-hôpitaux de Paris, 4, rue de la Chine, 75970 Paris cedex 20, France; Service de pneumologie, hôpital Tenon, Assistance Publique-hôpitaux de Paris, 4, rue de la Chine, 75970 Paris cedex 20, France.
authors.forename: Anne-Marie
authors.initials: AM
authors.lastname: Ruppert
authors.affiliation: Service de pneumologie, hôpital Tenon, Assistance Publique-hôpitaux de Paris, 4, rue de la Chine, 75970 Paris cedex 20, France.
authors.forename: Armelle
authors.initials: A
authors.lastname: Lavole
authors.affiliation: Service de pneumologie, hôpital Tenon, Assistance Publique-hôpitaux de Paris, 4, rue de la Chine, 75970 Paris cedex 20, France.
authors.forename: Nathalie
authors.initials: N
authors.lastname: Rozensztajn
authors.affiliation: Service de pneumologie, hôpital Tenon, Assistance Publique-hôpitaux de Paris, 4, rue de la Chine, 75970 Paris cedex 20, France; Service d'anatomie-pathologique, hôpital Tenon, Assistance Publique-hôpitaux de Paris, 4, rue de la Chine, 75970 Paris cedex 20, France.
authors.forename: Martine
authors.initials: M
authors.lastname: Antoine
authors.affiliation: GRC 04 UPMC, hôpital Tenon, Assistance Publique-hôpitaux de Paris, 4, rue de la Chine, 75970 Paris cedex 20, France; Service de pneumologie, hôpital Tenon, Assistance Publique-hôpitaux de Paris, 4, rue de la Chine, 75970 Paris cedex 20, France.
authors.forename: Jacques
authors.initials: J
authors.lastname: Cadranel
authors.affiliation: GRC 04 UPMC, hôpital Tenon, Assistance Publique-hôpitaux de Paris, 4, rue de la Chine, 75970 Paris cedex 20, France; Service de pneumologie, hôpital Tenon, Assistance Publique-hôpitaux de Paris, 4, rue de la Chine, 75970 Paris cedex 20, France. Electronic address: marie.wislez@tnn.aphp.fr.
authors.forename: Marie
authors.initials: M
authors.lastname: Wislez
mesh_terms: D000970:Antineoplastic Agents / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D002986:Clinical Trials as Topic; D005260:Female; D052138:Genes, Neoplasm; D006801:Humans; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000201:enzymology / Q000235:genetics; D008297:Male; D058990:Molecular Targeted Therapy; D009154:Mutation; D009363:Neoplasm Proteins / Q000037:antagonists & inhibitors* / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use; D015398:Signal Transduction / Q000187:drug effects
chemical_list: D000970:Antineoplastic Agents; D009363:Neoplasm Proteins; D047428:Protein Kinase Inhibitors
keywords: ACSé; ALK; Cancer bronchique non à petites cellules; EGFR; Mutation T790M; Non-small cell lung cancer; T790M resistance mutation